share_log

Piper Sandler Maintains Overweight on Inozyme Pharma, Lowers Price Target to $23

Benzinga ·  Mar 11 16:05

Piper Sandler analyst Allison Bratzel maintains Inozyme Pharma (NASDAQ:INZY) with a Overweight and lowers the price target from $30 to $23.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 260

Recommended

Write a comment